A new clinical KRAS degrader
Three private biotechs enter clinical trials, one targeting KRAS.
Reality hits Nuvation
Early Ibtrozi sales and a low-cost licensing deal with Eisai disappoint investors.
Ebvallo gets a second US knockback
Things look grim for Atara, which had been relying on a milestone from Pierre Fabre.
AbbVie is next to the VEGF bispecific table
$650m buys the group rights to RemeGen’s RC148.
Eikon tries to follow Aktis
After Aktis's $318m flotation Eikon is a bigger proposition.
CG Oncology gets an intermediate-risk bladder boost
Readout of the Pivot-006 trial is brought forward by nearly a year.
No checkpoint glory for Acrivon
Prexasertib data worsen again, and biomarkers are up in the air.
Rakuten sheds light on its conjugate
The company secures funding to push its lead candidate towards US approval.
